BusinessCase MagnesiumSulfate web

Pre-eclampsia and eclampsia (PE/E), or hypertensive disorder during pregnancy, are responsible for
10–15% of the world’s maternal deaths, or approximately 52,000 deaths per year. Pre-eclampsia develops during pregnancy and affects around 2–8% of all pregnant women. If the disease is not identified
early, it can lead to seizures, organ failure, and ultimately the death of the mother and her fetus. PE/E
can be treated by delivering the baby or by administering magnesium sulfate to the pregnant woman.
Magnesium sulfate is on the World Health Organization’s (WHO’s) Model List of Essential Medicines 1
and is on the UN Commission on Life-Saving Commodities list of lifesaving drugs. In many developing
countries, the drug is on the national Essential Medicines List, but is either not the first line of treatment
or other drugs are also listed as first-line treatment. Magnesium sulfate should be the sole first-line treat-
ment; diazepam can be used if magnesium sulfate is
not available.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>